Diabetes Therapeutics Market By Product (Injectables, Oral antidiabetic Drugs): Global Opportunity Analysis and Industry Forecast, 2020-2030

Diabetes Therapeutics Market

Diabetes therapeutic is a drug used by diabetic patients to restore the blood glucose metabolism to a normal state. It includes insulin analogues and oral hypoglycemic agents.

The factors that drive the global diabetes therapeutics market growth include rise in geriatric population, increase in the prevalence of diabetes worldwide, sedentary lifestyle of people, development of affordable & effective diabetes therapeutics, growth in awareness among population about self-management of diabetes, and increase in support from the government.  For instance, according to American Diabetes Association (ADA), in 2019, approximately  37.3 million Americans were diagnosed with diabetes. Moreover, surge in awareness of diabetes care and market potential in developing regions are expected to provide numerous opportunities for diabetes market share by company. However, side effects of diabetic drugs and stringent approval process for these drugs restrict diabetes therapeutics market trends.

Depending on product, the market is bifurcated into injectables and oral-antidiabetic drugs (OAD). The injectables segment is the highest contributor to the market growth owing to increase in prevalence of diabetes. The oral-antidiabetic drugs segment is anticipated to be lucrative for market players due to increase in prevalence of type 2 diabetes and rise in geriatric population.

North America was the leading revenue contributor to the global diabetes therapeutics market share in 2020, and is expected to remain dominant throughout the forecast period. This is attributed to its well-developed healthcare industry, increase in geriatric population, and high prevalence rate of diabetes. However, Asia-Pacific is expected to grow at the highest CAGR of 11.2% during the forecast period, due to increase in the number of diabetes patients, high population base, and growth in disposable income in the region.

The top 10 diabetes drugs key players operating in the global diabetes therapeutics market include Astrazeneca Plc., Boehringer Ingelheim GmbH, Eli Lilly and Company, Glaxosmithkline Plc., Johnson & Johnson, Merck & Co., Inc., Novartis Ag, Novo Nordisk, Sanofi S.A., and Takeda Pharmaceutical Company Limited.

The COVID-19 outbreak is anticipated to have a negative impact on the growth of the diabetes therapeutics market. There was implementation of lockdown to control spread of COVID-19. Many hospitals were converted into COVID 19 centers due to which diabetics faced delays in treatment. For instance, according to the World Health Organization (WHO) report, as of December 19, 2021, over 273 million cases and over 5.3 million deaths have been reported globally. Furthermore, entire healthcare sector’s focus shifted toward COVID-19. Thus, COVID-19 adversely affected the growth of the diabetes therapeutics market..

Key Findings of Study

On the basis of products, the injectables segment was the highest contributor in 2020.

Region wise, North America garnered the largest revenue share in 2020, whereas Asia is anticipated to grow at the highest CAGR during the forecast period.

Overview

The global diabetes therapeutics market was valued at $118,063.3 million in 2020, and is projected to reach $317,915 million by 2030, registering a CAGR of 10.4% from 2021 to 2030. Diabetes is a chronic metabolic disorder in which there are abnormalities in blood glucose levels. Diabetes therapeutics are drugs used by diabetic patients to conserve the blood glucose levels in the body.

The global diabetes therapeutics market is expected to register substantial growth in the near future, owing to rise in prevalence of diabetes, high obesity, sedentary lifestyles, and other chronic conditions. For instance, according to International Diabetes Federation (IDF),Diabetes Atlas, in 2021, approximately 537 million adults (20-79 years of age) were living with diabetes.  Furthermore, rise in geriatric population led to an increase in growth of diabetes therapeutics market. However, side effects caused by anti-diabetes medication hamper the market growth during the forecast period. Conversely, increase in funding for R&D activities in diabetes sector is expected to offer remunerative opportunities for market players.

The diabetes therapeutics market is segmented into product and region. By product, the market is categorized into injectables and oral-antidiabetic drugs (OAD). By region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, Taiwan, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The key players operating in the global diabetes therapeutics market include Astrazeneca Plc., Boehringer Ingelheim GmbH, Eli Lilly and Company, Glaxosmithkline Plc., Johnson & Johnson, Merck & Co., Inc., Novartis Ag ,Novo Nordisk, Sanofi S.A., and Takeda Pharmaceutical Company Limited.

KEY BENEFITS FOR STAKEHOLDERS

●The report provides an in-depth analysis of the global diabetes therapeutics market size along with the current trends and future estimations to elucidate the future investment pockets.

●It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.

●A comprehensive analysis of the region helps to understand the regional market, facilitate strategic business planning, and determine prevailing opportunities.

●The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global diabetes therapeutics market growth.

 

Key Market Segments

○ MERCK and CO., INC

Scope of Diabetes Therapeutics Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Injectables

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market analysis by country

4.3 Oral antidiabetic Drugs

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 North America

5.2.1 Key trends and opportunities

5.2.2 North America Market size and forecast, by Product

5.2.3 North America Market size and forecast, by country

5.2.3.1 U.S.

5.2.3.1.1 Market size and forecast, by Product

5.2.3.2 Canada

5.2.3.2.1 Market size and forecast, by Product

5.2.3.3 Mexico

5.2.3.3.1 Market size and forecast, by Product

5.3 Europe

5.3.1 Key trends and opportunities

5.3.2 Europe Market size and forecast, by Product

5.3.3 Europe Market size and forecast, by country

5.3.3.1 Germany

5.3.3.1.1 Market size and forecast, by Product

5.3.3.2 France

5.3.3.2.1 Market size and forecast, by Product

5.3.3.3 United Kingdom

5.3.3.3.1 Market size and forecast, by Product

5.3.3.4 Italy

5.3.3.4.1 Market size and forecast, by Product

5.3.3.5 Spain

5.3.3.5.1 Market size and forecast, by Product

5.3.3.6 Rest of Europe

5.3.3.6.1 Market size and forecast, by Product

5.4 Asia-Pacific

5.4.1 Key trends and opportunities

5.4.2 Asia-Pacific Market size and forecast, by Product

5.4.3 Asia-Pacific Market size and forecast, by country

5.4.3.1 China

5.4.3.1.1 Market size and forecast, by Product

5.4.3.2 Japan

5.4.3.2.1 Market size and forecast, by Product

5.4.3.3 India

5.4.3.3.1 Market size and forecast, by Product

5.4.3.4 Australia

5.4.3.4.1 Market size and forecast, by Product

5.4.3.5 Rest Of Asia Pacific

5.4.3.5.1 Market size and forecast, by Product

5.5 LAMEA

5.5.1 Key trends and opportunities

5.5.2 LAMEA Market size and forecast, by Product

5.5.3 LAMEA Market size and forecast, by country

5.5.3.1 Brazil

5.5.3.1.1 Market size and forecast, by Product

5.5.3.2 Saudi Arabia

5.5.3.2.1 Market size and forecast, by Product

5.5.3.3 South Africa

5.5.3.3.1 Market size and forecast, by Product

5.5.3.4 Rest of LAMEA

5.5.3.4.1 Market size and forecast, by Product

6.1. Introduction

6.2. Top winning strategies

6.3. Product Mapping of Top 10 Player

6.4. Competitive Dashboard

6.5. Competitive Heatmap

6.6. Key developments

7.1 ASTRAZENECA PLC

7.1.1 Company overview

7.1.2 Company snapshot

7.1.3 Operating business segments

7.1.4 Product portfolio

7.1.5 Business performance

7.1.6 Key strategic moves and developments

7.2 BOEHRINGER INGELHEIM GMBH

7.2.1 Company overview

7.2.2 Company snapshot

7.2.3 Operating business segments

7.2.4 Product portfolio

7.2.5 Business performance

7.2.6 Key strategic moves and developments

7.3 ELI LILLY AND COMPANY

7.3.1 Company overview

7.3.2 Company snapshot

7.3.3 Operating business segments

7.3.4 Product portfolio

7.3.5 Business performance

7.3.6 Key strategic moves and developments

7.4 GLAXOSMITHKLINE PLC

7.4.1 Company overview

7.4.2 Company snapshot

7.4.3 Operating business segments

7.4.4 Product portfolio

7.4.5 Business performance

7.4.6 Key strategic moves and developments

7.5 NOVARTIS AG

7.5.1 Company overview

7.5.2 Company snapshot

7.5.3 Operating business segments

7.5.4 Product portfolio

7.5.5 Business performance

7.5.6 Key strategic moves and developments

7.6 NOVO NORDISK

7.6.1 Company overview

7.6.2 Company snapshot

7.6.3 Operating business segments

7.6.4 Product portfolio

7.6.5 Business performance

7.6.6 Key strategic moves and developments

7.7 SANOFI S.A.

7.7.1 Company overview

7.7.2 Company snapshot

7.7.3 Operating business segments

7.7.4 Product portfolio

7.7.5 Business performance

7.7.6 Key strategic moves and developments

7.8 TAKEDA PHARMACEUTICAL COMPANY LIMITED

7.8.1 Company overview

7.8.2 Company snapshot

7.8.3 Operating business segments

7.8.4 Product portfolio

7.8.5 Business performance

7.8.6 Key strategic moves and developments

7.9 johnson and johnson md&d

7.9.1 Company overview

7.9.2 Company snapshot

7.9.3 Operating business segments

7.9.4 Product portfolio

7.9.5 Business performance

7.9.6 Key strategic moves and developments

7.10 MERCK and CO., INC.

7.10.1 Company overview

7.10.2 Company snapshot

7.10.3 Operating business segments

7.10.4 Product portfolio

7.10.5 Business performance

7.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)

TABLE 2. DIABETES THERAPEUTICS MARKET REVENUE, FOR INJECTABLES, BY REGION , 2020-2030,($MILLION)

TABLE 3. DIABETES THERAPEUTICS MARKET INJECTABLES BY COUNTRY, 2020-2030,($MILLION)

TABLE 4. DIABETES THERAPEUTICS MARKET REVENUE, FOR ORAL ANTIDIABETIC DRUGS, BY REGION , 2020-2030,($MILLION)

TABLE 5. DIABETES THERAPEUTICS MARKET ORAL ANTIDIABETIC DRUGS BY COUNTRY, 2020-2030,($MILLION)

TABLE 6. DIABETES THERAPEUTICS MARKET, BY REGION, 2020-2030,($MILLION)

TABLE 7. NORTH AMERICA DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)

TABLE 8. NORTH AMERICA DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 9. U.S. DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 10. CANADA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 11. MEXICO DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 12. EUROPE DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)

TABLE 13. EUROPE DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 14. GERMANY DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 15. FRANCE DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 16. UNITED KINGDOM DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 17. ITALY DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 18. SPAIN DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 19. REST OF EUROPE DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 20. ASIA-PACIFIC DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)

TABLE 21. ASIA-PACIFIC DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 22. CHINA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 23. JAPAN DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 24. INDIA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 25. AUSTRALIA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 26. REST OF ASIA PACIFIC DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 27. LAMEA DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)

TABLE 28. LAMEA DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 29. BRAZIL DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 30. SAUDI ARABIA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 31. SOUTH AFRICA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 32. REST OF LAMEA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)

TABLE 33.ASTRAZENECA PLC: COMPANY SNAPSHOT

TABLE 34.ASTRAZENECA PLC: OPERATING SEGMENTS

TABLE 35.ASTRAZENECA PLC: PRODUCT PORTFOLIO

TABLE 36.ASTRAZENECA PLC: NET SALES,

TABLE 37.ASTRAZENECA PLC: KEY STRATERGIES

TABLE 38.BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT

TABLE 39.BOEHRINGER INGELHEIM GMBH: OPERATING SEGMENTS

TABLE 40.BOEHRINGER INGELHEIM GMBH: PRODUCT PORTFOLIO

TABLE 41.BOEHRINGER INGELHEIM GMBH: NET SALES,

TABLE 42.BOEHRINGER INGELHEIM GMBH: KEY STRATERGIES

TABLE 43.ELI LILLY AND COMPANY: COMPANY SNAPSHOT

TABLE 44.ELI LILLY AND COMPANY: OPERATING SEGMENTS

TABLE 45.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO

TABLE 46.ELI LILLY AND COMPANY: NET SALES,

TABLE 47.ELI LILLY AND COMPANY: KEY STRATERGIES

TABLE 48.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT

TABLE 49.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS

TABLE 50.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO

TABLE 51.GLAXOSMITHKLINE PLC: NET SALES,

TABLE 52.GLAXOSMITHKLINE PLC: KEY STRATERGIES

TABLE 53.NOVARTIS AG: COMPANY SNAPSHOT

TABLE 54.NOVARTIS AG: OPERATING SEGMENTS

TABLE 55.NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 56.NOVARTIS AG: NET SALES,

TABLE 57.NOVARTIS AG: KEY STRATERGIES

TABLE 58.NOVO NORDISK: COMPANY SNAPSHOT

TABLE 59.NOVO NORDISK: OPERATING SEGMENTS

TABLE 60.NOVO NORDISK: PRODUCT PORTFOLIO

TABLE 61.NOVO NORDISK: NET SALES,

TABLE 62.NOVO NORDISK: KEY STRATERGIES

TABLE 63.SANOFI S.A.: COMPANY SNAPSHOT

TABLE 64.SANOFI S.A.: OPERATING SEGMENTS

TABLE 65.SANOFI S.A.: PRODUCT PORTFOLIO

TABLE 66.SANOFI S.A.: NET SALES,

TABLE 67.SANOFI S.A.: KEY STRATERGIES

TABLE 68.TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT

TABLE 69.TAKEDA PHARMACEUTICAL COMPANY LIMITED: OPERATING SEGMENTS

TABLE 70.TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO

TABLE 71.TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET SALES,

TABLE 72.TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATERGIES

TABLE 73.JOHNSON AND JOHNSON MD&D: COMPANY SNAPSHOT

TABLE 74.JOHNSON AND JOHNSON MD&D: OPERATING SEGMENTS

TABLE 75.JOHNSON AND JOHNSON MD&D: PRODUCT PORTFOLIO

TABLE 76.JOHNSON AND JOHNSON MD&D: NET SALES,

TABLE 77.JOHNSON AND JOHNSON MD&D: KEY STRATERGIES

TABLE 78.MERCK AND CO., INC.: COMPANY SNAPSHOT

TABLE 79.MERCK AND CO., INC.: OPERATING SEGMENTS

TABLE 80.MERCK AND CO., INC.: PRODUCT PORTFOLIO

TABLE 81.MERCK AND CO., INC.: NET SALES,

TABLE 82.MERCK AND CO., INC.: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.DIABETES THERAPEUTICS MARKET SEGMENTATION

FIGURE 2.DIABETES THERAPEUTICS MARKET,2020-2030

FIGURE 3.DIABETES THERAPEUTICS MARKET,2020-2030

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.DIABETES THERAPEUTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.DIABETES THERAPEUTICS MARKET,BY PRODUCT,2020(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF INJECTABLES DIABETES THERAPEUTICS MARKET,2020-2030(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ORAL ANTIDIABETIC DRUGS DIABETES THERAPEUTICS MARKET,2020-2030(%)

FIGURE 15.DIABETES THERAPEUTICS MARKET BY REGION,2020

FIGURE 16.U.S. DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)

FIGURE 17.CANADA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)

FIGURE 18.MEXICO DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)

FIGURE 19.GERMANY DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)

FIGURE 20.FRANCE DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)

FIGURE 21.UNITED KINGDOM DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)

FIGURE 22.ITALY DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)

FIGURE 23.SPAIN DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)

FIGURE 24.REST OF EUROPE DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)

FIGURE 25.CHINA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)

FIGURE 26.JAPAN DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)

FIGURE 27.INDIA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)

FIGURE 28.AUSTRALIA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)

FIGURE 29.REST OF ASIA PACIFIC DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)

FIGURE 30.BRAZIL DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)

FIGURE 31.SAUDI ARABIA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)

FIGURE 32.SOUTH AFRICA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)

FIGURE 33.REST OF LAMEA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)

FIGURE 34. TOP WINNING STRATEGIES, BY YEAR

FIGURE 35. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 36. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 37.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 38.COMPETITIVE DASHBOARD

FIGURE 39.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 40.ASTRAZENECA PLC.: NET SALES ,($MILLION)

FIGURE 41.BOEHRINGER INGELHEIM GMBH.: NET SALES ,($MILLION)

FIGURE 42.ELI LILLY AND COMPANY.: NET SALES ,($MILLION)

FIGURE 43.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)

FIGURE 44.NOVARTIS AG.: NET SALES ,($MILLION)

FIGURE 45.NOVO NORDISK.: NET SALES ,($MILLION)

FIGURE 46.SANOFI S.A..: NET SALES ,($MILLION)

FIGURE 47.TAKEDA PHARMACEUTICAL COMPANY LIMITED.: NET SALES ,($MILLION)

FIGURE 48.JOHNSON AND JOHNSON MD&D.: NET SALES ,($MILLION)

FIGURE 49.MERCK AND CO., INC..: NET SALES ,($MILLION